GMAB N Stock Overview
Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Genmab A/S Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | kr.5,100.00 |
52 Week High | kr.5,375.45 |
52 Week Low | kr.4,907.84 |
Beta | 0.79 |
1 Month Change | 0% |
3 Month Change | 3.92% |
1 Year Change | n/a |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -14.84% |
Recent News & Updates
Recent updates
Shareholder Returns
GMAB N | MX Biotechs | MX Market | |
---|---|---|---|
7D | 0% | 0% | 0% |
1Y | n/a | 0% | 0% |
Return vs Industry: Insufficient data to determine how GMAB N performed against the MX Biotechs industry.
Return vs Market: Insufficient data to determine how GMAB N performed against the MX Market.
Price Volatility
GMAB N volatility | |
---|---|
GMAB N Average Weekly Movement | n/a |
Biotechs Industry Average Movement | 0% |
Market Average Movement | 0% |
10% most volatile stocks in MX Market | 0% |
10% least volatile stocks in MX Market | 0% |
Stable Share Price: GMAB N has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine GMAB N's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1999 | 2,286 | Jan G.J. de Winkel | www.genmab.com |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab A/S Fundamentals Summary
GMAB N fundamental statistics | |
---|---|
Market cap | Mex$317.56b |
Earnings (TTM) | Mex$13.17b |
Revenue (TTM) | Mex$42.84b |
24.1x
P/E Ratio7.4x
P/S RatioIs GMAB N overvalued?
See Fair Value and valuation analysisEarnings & Revenue
GMAB N income statement (TTM) | |
---|---|
Revenue | kr.17.78b |
Cost of Revenue | kr.411.00m |
Gross Profit | kr.17.37b |
Other Expenses | kr.11.91b |
Earnings | kr.5.47b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 01, 2024
Earnings per share (EPS) | 84.64 |
Gross Margin | 97.69% |
Net Profit Margin | 30.74% |
Debt/Equity Ratio | 0% |
How did GMAB N perform over the long term?
See historical performance and comparison